PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Oct. 10, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ: OCRX ), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Linda Grais, M.D., Chief Executive Officer, will be presenting at the upcoming 2016 BIO Investor Forum being held October 18-19, 2016 at the Westin St. Francis Hotel in San Francisco, California. Ocera’s presentation will take place in the Elizabethan B Room at 8:30 AM Pacific Time.
A live audio webcast of the presentation will be available in the "Investors" section of Ocera's website, www.ocerainc.com . A replay of the presentation will be available for 60 days following the conference for those unable to listen live.
About Ocera
Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate) in both intravenous and oral formulations. OCR-002 is an ammonia scavenger and has been granted orphan drug designation and Fast Track status by the U.S. Food and Drug Administration (FDA) for the treatment of hyperammonemia and resultant hepatic encephalopathy in patients with acute liver failure and acute-on-chronic liver disease. For additional information, please see www.ocerainc.com .
OCRX-G
Contact: Susan Sharpe Ocera Therapeutics, Inc. contact@ocerainc.com 919-328-1109
